• Instagram
• LinkedIn
• X

In a move that could redefine the trajectory of cannabis in America, Acting Attorney General Todd Blanche has initiated a sweeping policy shift, one that pulls cannabis out of the most restrictive category under federal law and into a space that acknowledges its medical potential. For decades, cannabis has lived under the same classification as the most dangerous substances known to public health policy. Now, with a stroke of policy reform, that narrative is beginning to change.

According to a Justice Department announcement, Blanche confirmed he has signed an executive order to immediately reschedule FDA-approved marijuana and state-licensed marijuana from Schedule I to Schedule III. The decision also includes an order for an “expedited hearing” aimed at evaluating broader changes to cannabis’s classification under federal law.

For context, Schedule I drugs, where cannabis has resided since the Nixon era, are defined as substances with no accepted medical use and a high potential for abuse. This category includes heroin, LSD, and ecstasy, a classification that has long been challenged by scientists, medical professionals, and advocates alike.

Under the proposed reclassification, cannabis will move into Schedule III, defined as “drugs with a moderate to low potential for physical and psychological dependence.” This shift signals a notable recalibration in how federal authorities perceive the plant, not as a high-risk narcotic, but as a substance with measurable therapeutic potential.

Blanche underscored the broader implications of the move, stating:  “The Department of Justice is delivering on President Trump’s promise to expand Americans’ access to medical treatment options,” and further emphasized, “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.”

The Justice Department also confirmed that a June 29 hearing will “evaluate broader changes to marijuana’s status under federal law,” suggesting that this action may be just the beginning of a more comprehensive federal reassessment.

This development follows a December executive order signed by President Trump aimed at fast-tracking cannabis reclassification. While the order stops short of federal legalization, it marks a decisive step toward reducing regulatory barriers that have historically limited both access and scientific inquiry.

Behind the scenes, momentum has been building. A White House official noted that efforts are underway to move “expeditiously” in implementing the order, with a focus on increasing medical research and “to close the gap between current medical marijuana use and medical knowledge.”

Scientists, long constrained by the limitations of Schedule I classification, are now positioned to explore cannabis with greater depth and legitimacy. Early reactions suggest optimism that this policy shift will unlock critical research pathways, particularly in understanding cannabis’s impact across a range of medical conditions.

For athletes, this isn’t just policy, it’s progress. The reclassification of cannabis could directly influence how sports organizations, medical teams, and recovery specialists approach treatment protocols. From managing chronic pain and inflammation to supporting mental health and recovery cycles, cannabis has increasingly become part of the athlete conversation. With expanded research now within reach, teams and governing bodies may finally gain the clinical data needed to make informed decisions, bridging the long-standing gap between anecdotal use and evidence-based application in sport.